Jazz's Ziihera Beats Trastuzumab on Survival in Phase 3 GEA Trial
Image
September 03, 2026 – Dublin -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that Ziihera (zanidatamab-hrii) plus chemotherapy achieved a statistically significant and clinically meaningful overall survival benefit over trastuzumab plus chemotherapy in first-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma (GEA), based on a second interim analysis of the Phase 3 HERIZON-GEA-01 trial.
Ziihera's survival hazard ratio improved from the first interim analysis
The Ziihera plus chemotherapy arm showed an improved OS hazard ratio compared with the trial's first interim readout, according to Jazz. The company said the safety profile remained consistent with prior HERIZON-GEA-01 data and each agent's known profile, with no new safety signals identified.